Skip to main content
OET ONLINE TRAINING @ $44

Sample OET writing ....



 I am writing to refer Mr. Billy. He is suffering from basal cell carcinoma of neck. He requires further care and support from your facility as he is due for discharge today.

 Mr billy admitted to our hospital on 21/06/2011 due to skin-related issues, and he has undergone skin biopsy for pathological studies, which confirmed his diagnosis / he has basal cell carcinoma. Therefore removal of basal cell carcinoma performed. As part of pain management, he commenced on panadene forte 500 mg. In general, he has no complication reported during hospitalization.

 Mr billy lives with his wife. He is a regular smoker and drinker for the past 30 years.

After discharge, please monitor him daily to find complications. Besides, he can continue medication one more week. In case of emergency, please contact his wife Jennifer, her contact details attached with this letter

Thank you for taking Mr.billy into your care. Please do not hesitate to contact me if you have any quires.

Labels

Labels:
Location: Toronto, ON, Canada

Comments

  1. Bibin EaloorApril 13, 2020 at 7:48 AM

    As a nurse looking OET Online for Nurses, I found this article very helpful.

    ReplyDelete
  2. Pamela WeberNovember 21, 2020 at 12:08 AM

    Great Article! I got too much information from this post. Thanks for sharing such a helpful article. Click here for more information about it

    ReplyDelete

Post a Comment

Popular posts from this blog

Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Abstract BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial . METHODS We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. RESULTS At a minimum follow-up of 60 months, the median overall survival was more...
Post a Comment
Read more
  OET SAMPLE LETTER - Robyn Harwood                            WINNER ONLINE OET I am writing to request a home visit for Ms. Harwood. She is diagnosed with right partial rotator cuff tear. She requires care and assistance from your facility.                                                                                                                   Or                                                                      ...
Post a Comment
Read more